OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO Combined with KEYTRUDA for Late-Stage Metastatic Melanoma
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced it has entered into a Clinical Trial Collaboration and Supply Agreement with Merck to to evaluate the combination of OncoSec's DNA-plasmid interleukin-12
July 7, 2021
by firstwordpharma
OncoSec Appoints Brian Leuthner as Interim CEO
OncoSec Medical Incorporated (NASDAQ:ONCS) today announced that Daniel O'Connor has resigned and that Brian Leuthner, formerly Chief Operating Officer, has been appointed Interim Chief Executive Officer, effective June 25, 2021.
June 25, 2021
by firstwordpharma
OncoSec Announces First Subjects Dosed in Phase 1 Trial of COVID-19 Vaccine
OncoSec Medical Incorporated has dosed several subjects in its Phase 1 clinical trial of CORVax12, the only vaccine candidate to include an immunostimulatory cytokine to address COVID-19.
January 28, 2021
by americanpharmaceuticalreview
Sirtex Medical announces collaboration update with OncoSec Medical
Sirtex Medical US Holdings, Inc. announced an advancement in its strategic collaboration with OncoSec Medical, Inc. relating to OncoSec's lead product candidate TAVO™ (tavokinogene telseplasmid) and its electroporation (EP) gene delivery system.
January 20, 2021
by prnasia
OncoSec Announces FDA Clearance for Trial of COVID-19 Vaccine Candidate
OncoSec Medical announced the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for a first-in-human Phase 1 trial for CORVax12, a novel DNA-encodable vaccine against SARS-CoV-2 that the Company ...
November 9, 2020
by americanpharmaceuticalreview
OncoSec Announces Initiation of aStudy to Evaluate Melanoma Treatment
OncoSec Medical Incorporated announced the commencement of an investigator-initiated Phase 2 study led by Senior Member and Professor Ahmad A. Tarhini, M.D., Ph.D. of the H. Lee Moffitt Cancer Center and Research Institute and ...
August 31, 2020
by americanpharmaceuticalreview
OncoSec Releases Presentation Spotlighting the Benefits of the Proposed CGP/Sirtex Transaction and Partnership
In the presentation, OncoSec also addresses the ongoing attempts by Alpha Holdings, Inc. ("Alpha") to prevent the special meeting to vote on the Transaction from ever happening by resorting to litigation and a potentially disenfranchising proxy scheme.
December 22, 2019
by firstwordpharma
OncoSec Releases Interim Data from Ongoing Study of TAVO, KEYTRUDA® Combo
OncoSec Medical has announced interim data from KEYNOTE-890, an ongoing Phase 2 study of TAVO™ (intratumoral IL-12) in combination with KEYTRUDA® in patients with heavily pretreated ...
May 23, 2019
by americanpharmaceuticalreview
OncoSec Granted Exclusive Worldwide Rights to Patent Portfolio for Use of IL-12 DNA
OncoSec announced the Company has been granted exclusive worldwide rights to Gaeta Therapeutics' portfolio of patents and applications covering the combination use of IL-12 DNA and ...
May 22, 2019
by americanpharmaceuticalreview
OncoSec, Gynecologic Oncology Group to Conduct Study of TAVO with KEYTRUDA
OncoSec has established a collaboration with the GOG Foundation to conduct a registration-enabled study of TAVO (tavokinogene telseplasmid) in women with recurrent/persistent cervical cancer (OMS-150)......
January 9, 2019
by americanpharmaceuticalreview
OncoSec Doses First Patient in KEYNOTE-890 Phase 2 Clinical Trial
OncoSec announced the first patient has been treated in KEYNOTE-890, a Phase 2 clinical trial for the treatment of late-stage triple negative breast cancer (TNBC) with TAVO (intratumoral plasma encoded IL-12, or tavokinogene telseplasmid, plus electropora
November 10, 2018
by americanpharmaceuticalreview
OncoSec Appoints Chief Clinical Development Officer
The award was given in recognition of the exemplary contributions to the profession and improvement of society in line with the mission of FAPA in Asia
October 30, 2018
by expressbpd